WHC is still in active development. Read this to understand our approach.
depiction of CBQGYUDMJHNJBX-UHFFFAOYSA-N.svg
isomerdesign

Reboxetine

Verificar en isomerdesign

pubchem

Reboxetine

Verificar en pubchem

drugmap

Reboxetine

Verificar en drugmap

drugmap

Reboxetine

Verificar en drugmap

wiki

Reboxetine

Verificar en wiki

wiki

Esreboxetine

Verificar en wiki

Data

InChI: InChI=1S/C19H23NO3/c1-2-21-16-10-6-7-11-17(16)23-19(15-8-4-3-5-9-15)18-14-20-12-13-22-18/h3-11,18-20H,2,12-14H2,1H3

Sinónimos: REBOXETINE [HSDB], (R,R)-Reboxetine, Tocris-1982, Esreboxetine [USAN:INN],98769-81-4,BCP12060, Prolift,UNII-947S0YZ36I, DTXSID1048257, CHEMBL383921,(2r)-2-[(R)-(2-Ethoxyphenoxy)(Phenyl)methyl]morpholine, AKOS015966368, 2-((2-ethoxyphenoxy)benzyl)morpholine methanesulfonate, AK431803,947S0YZ36I,Reboxetine, (S,S)-( )-Reboxetine,A837261,CHEMBL383921, UNII-L8S50ZY490, NCGC00025335-01,DB00234, CHEBI:135342, Solvex, HSDB 7701,BDBM388642,2-[(2-ethoxyphenoxy)-phenyl-methyl]morpholine,DTXSID1048257,Morpholine, 2-((R)-(2-ethoxyphenoxy)phenylmethyl)-, (2R)-rel-,Reboxetine [INN:BAN],105017-38-7,CHEBI:135342,D95753, DB00234, Norebox,EN300-19659906, Morpholine, 2-[(2-ethoxyphenoxy)phenylmethyl]-, (R*,R*)-,(+/-)-(2R*)-2-((.ALPHA.R*)-.ALPHA.-(O-ETHOXYPHENOXY)BENZYL)MORPHOLINE,Morpholine, 2-[(R)-(2-ethoxyphenoxy)phenylmethyl]-, (2R)-rel-, AJ-47614, Reboxetine mesylate, MolPort-005-943-618, (2r)-2-[(R)-(2-Ethoxyphenoxy)(Phenyl)methyl]morpholine, (2S)-2-[(S)-(2-ethoxyphenoxy)-phenylmethyl]morpholine,AKOS015966368,REBOXETINE [WHO-DD],Reboxetine [INN], SCHEMBL34533, Edronax (TN), Morpholine, 2-((R)-(2-ethoxyphenoxy)phenylmethyl)-, (2R)-rel-,(S,S)-reboxetine,Esreboxetine, L8S50ZY490, Reboxetine [INN:BAN], Davedax,US9944618, Compound ID No. 178,REBOXETINE [VANDF],D08472,Reboxe- tine, 98819-76-2, AC1L2RJ0,DTXSID401315414,(R)-2-((R)-(2-ethoxyphenoxy)(phenyl)methyl)morpholine, ZINC3996032,AB00920697_06,41X,Norebox,Reboxitine, AN-34535,71620-89-8,ZINC3996032,(2R)-2-[(R)-(2-ethoxyphenoxy)-phenylmethyl]morpholine, SCHEMBL34534,REBOXETINE [MI], BCP12060, (2S)-2-[(S)-(2-ethoxyphenoxy)-phenyl-methyl]morpholine, Esreboxetine (USAN/INN),HSDB 7701, (S,S)-Reboxetine,Morpholine, 2-[(2-ethoxyphenoxy)phenylmethyl]-, (R*,R*)-,(R,R)-Reboxetine,R,R-reboxetine,(R,R)-(-)-Reboxetine, (+-)-(2R*)-2-((alphaR*)-alpha-(o-Ethoxyphenoxy)benzyl)morpholine, Morpholine, 2-[(R)-(2-ethoxyphenoxy)phenylmethyl]-, (2R)-rel-,AS-56251, S-Reboxetine,SCHEMBL34533,Reboxetine (INN), PNU 165442g, (2S)-2-[(S)-2-ethoxyphenoxy(phenyl)methyl]morpholine,Edronax (TN), PNU-165442G

Estimated data

Solubilidad: -2.933 (log(S) in mol/L prediction using SolTranNet)

Blood Brain Barrier Permeability: Yes (prediction using frontiersin.org)

Addictivity Prediction: 32.0% (prediction based on www.mdpi.com)

Similitudes

The following is a set of comparisons to understand the properties of this compound. This is still higly experimental and is still under active development. Please refer to our series of blog posts to fully understand our approach and its limitations. This information is for informational purposes only and should not be construed as medical advice.